Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00B0DZML60 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.375p -11.54% 2.875p 2.75p 3.00p 3.25p 2.875p 3.25p 17,324,666.00 15:04:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -12.8 -0.4 - 90.83

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron Forums and Chat

Date Time Title Posts
02/12/201621:31ReNeuron - a leading, clinical-stage stem cell business5,081.00
21/6/201617:11Brexit...time to buy2.00
13/6/201606:22Us/japan-
07/6/201608:31ReNeuron - The New Positive Thread108.00
05/6/201616:51Mms playing silly games this morning1.00

Add a New Thread

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:15:053.002,500,00075,000.00O
17:15:053.002,500,00075,000.00O
16:31:443.00400,00012,000.00O
16:29:433.0093,3362,799.99O
16:29:133.0016,167484.99O
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

DateSubject
02/12/2016
08:20
Reneuron Daily Update: Reneuron Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 3.25p.
Reneuron Group has a 4 week average price of 2.64p and a 12 week average price of 2.57p.
The 1 year high share price is 3.88p while the 1 year low share price is currently 2.25p.
There are currently 3,159,256,868 shares in issue and the average daily traded volume is 5,249,386 shares. The market capitalisation of Reneuron Group is £90,828,634.96.
30/10/2016
18:16
fredd1eboy: ReNeuron ready to rally Share 14:45 28 Oct 2016 The ‘King of Charts’ Zak Mir reckons ReNeuron Group Plc’s (LON:RENE) shares are set for a rally in the coming weeks after drifting lower over the past year or so. In the latest segment of the TIP TV Proactive Bulletin Board series, Mir says that the fundamentals for the firm seem to be solid, and he expects the share price to benefit as a result. “[There’s] an early bird opportunity here,” the technical analyst claims. “[The chart shows] some bullish divergence there so that does suggest that [shares could] rally over the next few weeks.”
29/9/2016
10:56
johnb5: This share will take 3-5 years to reach its potential. Of course there's huge risk but the reward potential is also huge. Share price recovery will depend on positive clinical trial data, next update on the stroke therapy due before year end, as Freddie has pointed out. Also big seller in the background isn't helping, which is also causing weak PI's to capitulate.
06/6/2016
09:00
buffythebuffoon: Noteworthy, I can only assume you are a short term trader, and an inexperienced one at that. Posting 'Reneuron a 50 bagger' on numerous boards is not only irritating, but a complete waste of time. As for anyone having a blockbuster success, there's quite a way to go. Obviously being able to bypass the blood-brain barrier by 'injecting straight into the brain' sounds like an exciting development, but it brings with it other challenges and risks. While I accept good money will be made here well in advance of any cleared treatment, we are a little way away from that point. No amount of pumping, certainly in the unsophisticated way you are adopting, will make any difference to the share price. Buffy
20/5/2016
18:21
yajnas01: I was an investor in reneuron ages ago - stopped following it Curious to know whether this is worth investing in again... Sentiment seems quite good again Can anyone help me and any new or returning investors get up to speed? Last time got tired of waiting as the share price never rose!!
11/5/2016
10:15
city chappy: The fundraising last year was an institutional placing, done at a premium to the share price and included institutions that had previously provided funding because they know the value being created and can weigh up the risk-reward better now than in the early days of biotechs. The company expects to make marketing applications for stroke and retinitis pigmentosa in 2018, the latter being via the FDA's "fast track" route to approval. To some extent the precise date to market of products is irrelevent because long before then the share price will rocket on any indication of success, such is the value to the markets being addressed. Additionally, they do not necessarily intend to take products to market themselves. They will consider all options, including outlicensing, selling inividual products or platforms, or selling the whole company.
09/5/2016
17:45
city chappy: ReNeuron gets Woodford's backing as it raises £68mln 12:56 10 Jul 2015 Olav Hellebø, Renueron’s chief executive, said it is the largest funding by a cell therapy group anywhere this year. ReNeuron gets Woodford's backing as it raises £68mln Neil Woodford's interest in ReNeuron is increasing to 35.5% Star fund manager Neil Woodford has increased his stake in stem cell therapy group ReNeuron (LON:RENE) through backing a hefty fund raise at a premium to the share price. ReNeuron is raising £68.4mln of which Woodford Investment Management is putting up almost half. Woodford, one of the UK's best known money managers, was a star performer at Invesco before branching out on his own. He is a major backer of UK biotechs and the launch earlier this year of Patient Capital, a trust focused on small caps and start-ups, pulled in hundreds of millions in new money. Olav Hellebø, ReNeuron’s chief executive, said it was the largest funding by a cell therapy group anywhere this year, underlining its position in the burgeoning stem cell therapy arena. Woodford Investment Management’s stake will rise to 35.5% from 26.63% with its new shares, though has been granted a waiver from having to make a mandatory offer. Woodford paid 5p for the shares, a small premium to the closing price yesterday. The funds will be sufficient to pay for ReNeuron’s existing therapeutic programmes through to 2019 and also early development of a new exosome nanomedicine platform targeting cancer. Stem cell treatments for strokes and retinitis pigmentosa are now fully funded to the commercial stage. Hellebø said he was delighted with the amount raised through the placing. “The proceeds will enable us to rapidly exploit the potential of our CTX, hRPC and exosome nanomedicine therapeutic platforms, providing multiple opportunities to build value for our shareholders. Results from the ongoing phase II clinical trial of its stroke treatment are due in the first half of next year with phase I data for critical limb ischaemia expected around the same time. Regulatory approval was recently given for a phase I/II trial of its retinitis pigmentosa treatment with a phase II/II trial scheduled for 2017. The exosome nanomedicine platform was also generating promising early pre-clinical data, Hellebø said. There was a loss for the year to March of £8.91mln (2014: £7.07mln). Shares surged 20% to 5.86p on the news, reflecting the heavyweight backing. Michael Hunt, ReNeuron’s chief financial officer, told Proactive that a positive hit in any of the programmes going through trials would add significant value from where the company stands now. The placing would allow it to concentrate on taking its programmes through their trials and possible commercialisation without the distraction of funding worries. Shares rose 0.97p to 5.85p valuing the company at £104mln.
09/5/2016
17:21
city chappy: Woodford increased his holding in Rene via his investment fund to 35% in the last Placing at 5p which was a premium to the share price. From Rene's website Woodford Investment Management 35.48% Wales Life Sciences Investment Fund 9.50% Invesco Limited 9.25% Aviva & its subsidiaries 6.34% The above information was last updated on Wednesday, 17 February 2016
04/4/2016
14:07
city chappy: Dendreon's share price soared from $0.3 billion in Feb 2009 to $7.3 billion in Apr 2010 on approval of its prostate cancer drug Provenge. Reneuron have a cancer treatment based on its exosome platform which in preclinical tests has repeatedly produced complete tumour collapse within three weeks of administration. It enters Phase 1 human trial next year. Any continued indication of success in treating cancer and Rene's shares will soar, with or without positive news from their other potentially transformational stroke and retinitis pigmentosa treatments. Rene have first mover advantage in the field of exosomes. If they target something like brain tumours, which are expensive and risky to treat surgically, they could be onto a winner. Starting to build a stake in Rene myself. The spread across three or four main areas (stroke, RP and cancer) spreads the risk and their strong cash balance means they could be self-funding until the likely target exit of a company take-over. This has the makings of a 50 bagger.
04/1/2016
16:36
ftangftang: ReNeuron Group PLC (LON:RENE) had its stock rating reiterated as ‘Buy’ in a report released by analysts at N+1 Singer. N+1 Singer today set a target price of 10 on the company’s stock. According to the analyst this now indicates there is a potential increase of 222.58% from ReNeuron Group PLC’s current price of 3.1. LON:RENE Over the last twelve months ReNeuron Group PLC’s stock price has increased by 0% from 0.00 to 3.1 . There are currently 2,058,105,000 shares in issue with a current share value of 3.1 giving ReNeuron Group PLC a market capitalisation of 63.80M GBp . ReNeuron Group PLC (LON:RENE) has a 50 day moving average of 2.92 and a 200 day moving average of 4.41. The 52 week high for the share price is 6.5 while the 52 week low for the stock is 2.26. ReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It develops cell-based therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Its ReNcell products are used in academic and commercial sectors. Its ReN009 stem cell candidate is for the treatment of critical limb ischaemia, a side effect of diabetes. This treatment is in early-stage clinical development. Its ReN003 stem cell candidate is for the treatment of retina pigmentosa, a blindness-causing disease of the retina. This treatment is in late pre-clinical development HTTP://www.risersandfallers.com/2016/01/04/reneuron-group-plc-lonrene-receives-buy-rating-from-n1-singer-analysts/ cheers ft ft
30/8/2015
13:03
rocket fuel: on admission 10 years ago the company had a mkt cap of £23.37m at a share price of 25p each. the company now has a mkt cap of £170m at a share price of 5.3p each. if on day two of admission the share price dropped to 5.3p the mkt cap would have been £4.4m today with the share price at 5.3p the mkt cap is £170m the difference between £4.4m and £170m is just a tad under 40x they floated 93.5m shares on admission and now have a grand total of 3.2bn shares and guess what? there is that 40x difference again. go figure boys n girls!
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161202 22:26:15